Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 24, Art. 26 (pp. 360-370)    |    2023       

»

Emergency prevention of gastrostasis in the cyclophosphamide myeloablative chemotherapy rat model

Vakunenkova O.A., Ivnitsky Ju.Ju., Krasnov K.A., Krasnova A.A.

«Golikov Research Center of Toxicology» of Federal Medico-Biological Agency of Russia

Brief summary

The effect of sodium bicarbonate (NaHCO3) administered by gavage on the formation of gastrointestinal stasis and urinary indican excretion was studied in a rat model of myeloablative cytostatic therapy with intravenous cyclophosphamide (CP). The introduction of CP at a dose of 390 mg/kg led to the development of gastrointestinal stasis within 24 hours with a predominance of gastrostasis and an increase in indican excretion. The introduction of NaHCO3 into the stomach of rats 30 minutes before and immediately after CP at a dose equivalent to 350 ml of its 4% solution for humans alleviated the manifestations of gastrostasis and overgrowth of indole-producing gastrointestinal microflora. The presented approach to emergency pharmaceutical prevention of gastrointestinal complications of myeloablative cytostatic pharmacotherapy is promising for testing when using not only CP as a cytostatic agent, but also other alkylating drugs.


Key words

cyclophosphamide; myeloablative cytostatic therapy; rat model; gastrostasis; indican; sodium bicarbonate; emergency prevention

Reference list

Shefer T.V., Ivnickii U.U., Reinuk V.L. Modelirovanie mieloablyacionnoi citostaticheskoi terapii soprovojdaetsya jelydochno-kishechnim stazom y kris. Medicina ekstremalnih sityacii.2022; (1): 51-55.


2. Jacobse J., Mensink H., Eileen M., Kollen W., Bresters D., Bredius R. Long-term aprepitant for nausea and vomiting associated with gastroparesis in hematopoietic cell transplantation. Bone Marrow Transplant.2018; 53(10): 1372-1374.


3. Shivarudraiah M., Patel A., Singh S. Acute severe gastroparesis (mega-stomach), an unusual complication of autologous stem cell transplantat: a case report. Canc. Res. Stat. Treat. 2022; 5(3): 584-587.


4. Patel R., Soni M., Soyantar B., Shivangi S., Sutaria S., Saraf M., Goswami D. A clash of quorum sensing vs quorum sensing inhibitors: an overview and risk of resistance. Arch. Microbiol.2023; 205(4): 107.


5. Buchholz B. M., Bauer A. J. Membrane Tlr signaling mechanisms in the gastrointestinal tract during sepsis. Neurogastroenterol. Motility.2010; (22): 232-245.


6. Chapman M. J., Nguyen N. Q., Deane A. M. Gastrointestinal dysmotility: clinical consequences and management of the critically ill patient. Gastroenterol. Clin. North Am.2011; 40(4); 725-739.


7. Grover M., Gianrico F., Stanghellini V. Gastroparesis: a turning point in understanding and treatment. Gut.2019; 68(12): 2238-2250.


8. Zheng T., Camilleri M. Management of gastroparesis. Gastroenterol. Hepatol.2021; 17(11): 515-525.


9. Sangild P.T., Shen R.L., Pontoppidan P., Rathe M. Animal models of chemotherapy-induced mucositis: translational relevance and challenges. Am. J. Physiol. Gastrointest. Tract Liver.2017; 314(2): 231-246.


10. Anderson L. W., Chen T. L., Colvin O. M., Grochow L. B., Collins J. M., Kennedy M. J. et al. Cyclophosphamide and 4-hydroxycyclophosphamide / aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy. Clin. Cancer. Res.1996; 2(9): 1481-1487.


11. Kuris G., Ambroziak W., Pietruszko R. Human aldehyde dehydrogenase. J. Biol. Chem.1989; 264(8): 4715-4721.


12. Tieze L., Neumann M., Fischer R., Rajewsky M., Jähde E. Proton-mediated liberation of aldophosphamide from a nontoxic prodrug: a strategy for tumor-selective activation of cytocidal drug. Canc. Res.1989; 49(15): 4179-4184.


13. Shefer T.V., Reinuk V.L., Malahovskii V.N., Ivnickii U.U. Otyagoshenie ostrih nevrologicheskih rasstroistv, vizvannih ciklofosfanom, pri iskysstvennom snijenii rN himysa y kris. Bul. Eksperim. Biol. Med.2012; 153(6): 841-846.


14. Reinuk V.L. Shefer T.V., Krasnov K.A., Ivnickii U.U. Vliyanie ciklofosfana i laktylozi na postyplenie ammiaka i veshestv srednei molyarnoi massi iz kishechnika v krov y kris. Bul. Eksperim Biol. Med.2012; 154(10): 455-459.


15. Seydoux C., Medinger M., Gerull S., Halter J., Heim D., Chalandon Y. et al. Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogenic hematopoietic cell transplantation: a prospective randomized trial. Ann. Hematol.2021; 100(1): 209-216.


16. Martinov V. L., Semenov A. G., Tylypov A. A., Chesnokov A. A., Kyrilov V. A., Kazarina N. V. Indikan mochi i vodorodnii dihatelnii test kak metodi skrining-diagnostiki sindroma izbitochnogo bakterialnogo rosta v tonkoi kishke. Med. Alm.2017; 2(47): 117-121.


17. Balahovskii S. D., Balahovskii I. S. Metodi himicheskogo analiza krovi.M.: Medgiz; 1953.


18. Zar J.H. Biostatistical Analysis. 5thPrentice-Hall/Pearson, Upper Saddle River: 2010.


19. O?Grady J., Murphy C.L., Burry L., Shanahan F., Buckly M. Defining gastrointestinal transit time using video capsule endoscopy: a study of healthy subjects. Endosc. Int. Open.2020; 8(3): E396-E400.


20. Yang L., Yan C., Zhang F., Jiang B., Gao S., Liang Y. et al. Effects of ketoconazole on cyclophosphamide metabolism: evaluation of CYP3A4 inhibition effect using the in vitro and in vivo models. Exp. Anim.2018; 67(1): 71-82.


21. Sahu K., Langeh U., Singh C., Singh A. Crosstalk between anticancer drugs and mitochondrial functions. Curr. Res. Pharmacol. Drug Discov.2021; (2): 100047.


22. Sunil V., Vayas K., Radbel J., Abramova E., Gow A., Laskin J., Laskin D. Impaired energy metabolism and altered functional activity of alveolar type II epithelial cell following exposure of rats to nitrogen mustard. Toxicol. Appl. Pharmacol.2022; 456: 116257.


23. Dahlgren D., Sjöblom M., Hellström P., Lennemäs H. Chemotherapeutics-induced intestinal mucositis: pathophysiology and potential treatment strategies. Front. Pharmacol.2021; 12 (Art. 681417): 1-12.